Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
AstraZeneca
McKesson
Moodys
Julphar
QuintilesIMS
UBS
Novartis
Fish and Richardson

Generated: February 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,746,691

« Back to Dashboard

Summary for Patent: 6,746,691
Title: Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
Abstract:Intermediate release nicotinic acid formulations having unique biopharmaceutical characteristics, which are suitable for oral administration once per day as a single dose preferably administered during the evening or at night for treating hyperlipidemia without causing drug-induced hepatotoxicity to such a level that requires the therapy to be discontinued, are disclosed. The intermediate nicotinic acid formulations can be administered as tablets in dosage strengths of, for example, 375 mg, 500 mg, 750 mg and 1000 mg. The 375 mg, 500 mg and 750 mg nicotinic acid tablets of the present invention have a dissolution curve similarity fit factor F.sub.2 of at least about 79, and the 1000 mg nicotinic acid tablets of the present invention have a dissolution curve similarity fit factor F.sub.2 of at least 44.
Inventor(s): Cefali; Eugenio A. (Lauderhill, FL)
Assignee: Kos Pharmaceuticals, Inc. (Miami, FL)
Application Number:08/962,424
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound; Dosage form; Device;

Drugs Protected by US Patent 6,746,691

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,746,691

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 6348198 ➤ Try a Free Trial
Norway 994275 ➤ Try a Free Trial
Australia 6454598 ➤ Try a Free Trial
Brazil 9815454 ➤ Try a Free Trial
Germany 69829042 ➤ Try a Free Trial
Canada 2574987 ➤ Try a Free Trial
Canada 2591710 ➤ Try a Free Trial
Finland 991896 ➤ Try a Free Trial
Norway 994248 ➤ Try a Free Trial
Canada 2283322 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Dow
Cerilliant
McKinsey
Healthtrust
Medtronic
Express Scripts
Fuji
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot